Wednesday, April 25, 2018 2:23:15 PM
I agree with your posts this morning re the line of thinking that the Parkinson’s trial should be our main focus, now that it will be concentrated on Parkinson dementia as opposed to motor skills.
Further, you are correct that a “win” in that trial will reveal the vast majority of the iceberg which lies beneath the surface of the “tip” which we all have our eyes trained upon.
Here’s a way of organizing the thought process which should be going on here, in my estimation.
In 1796, Edward Jenner successfully uses Cowpox contaminant to vaccinate human bodies from Smallpox. The idea of injecting a foreign bacteria into people for which their bodies already have the ability to produce antibodies against (cowpox), which is similar in nature to another bacteria for which no/insufficient antibodies were being produced to stave off death (smallpox), gave way to the success of the innovation of immunity through vaccine.
That was the “tip of the iceberg”. The start of a process which worked and which would repeatedly work going forward to immunize humans against a plethora of diseases.
It was not until 1885, almost 100 years later, that Louis Pasteur’s rabies vaccine impacted humanity. This gave rise to the Dawn of Bacteriology and through the 1930’s vaccines were developed against: diphtheria, tetanus, anthrax, cholera, plague, typhoid, tuberculosis. After a short span, polio was the next big killer to be stopped. And by the mid-20th century, vaccines had been successfully targeted to stop remaining childhood diseases including mumps, measles, rubella.
If Edward Jenner had the resources at his disposal in 1796 to go further than he did, he would have rightfully stated that his smallpox vaccine was just the “tip of the iceberg”. It was. But he didn’t (have the resources).
Alvin Toffler wrote the classic book, Future Shock, in 1970. In it, he described how the timeline of events which would change the course of history would be exponentially condensed going forward and gain speed by building upon knowledge gained preceding each major change.
We are witnessing the Future Shock effect in today’s world of medicine with the advent of DNA’s unraveling.
So, you are absolutely correct that once the short PD dementia trial is impacted by genetic biomarkers which will prove successful, many are the CNS diseases which have similar biomarkers that will fall.
Unlike, Edward Jenner, who did his part and ingeniously contributed to mankind by starting the fire, our company and compound have the harnessed power of highly concentrated resources, genetic biomarkers, and we will be able to burn down the entire CNS dark forest.
(Wow, Fireman, huge(!) apology for the analogy...it only just occurred to me you might see this in a different light. Don’t take it literally!)
Genetic biomarkers are the tip. Parkinson dementia trial will reveal more. Each successive CNS disease which comes after (along with all other maladies positively affected by cellular homeostasis restoration and mitochondrial function regeneration) will display the enormity of our sub-surface ice berg.
What if, no matter the mammoth size of this monster, the future holds safe passage for the Titanic? Immune from disaster of those tips jutting out, we sail on in safety, unscathed. Can’t wait to board the future ocean liners which will really be a taste of luxury, imo.
Thanks, McMagyar...Let’s keep the waterways safe for smooth sailing. Parkinson’s Dementia - Full steam ahead! Aye aye, Captain!!!
GLTA,
Bio
Recent AVXL News
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM